VolitionRx (NYSE:VNRX) Earns Buy Rating from D. Boral Capital

Key Points

• VolitionRx has had its "buy" rating restated by D. Boral Capital with a price target of $5.00, while Jones Trading upgraded it to a "strong-buy" with a $3.00 target price.
• The company's stock price was up 4.8% to $0.63 during midday trading, with an average rating of "Buy" and a consensus target price of $3.50.
• Insiders, including the CEO and a director, purchased a total of 171,250 shares recently, indicating strong confidence in the company's future performance.

VolitionRx (NYSE:VNRX - Get Free Report)'s stock had its "buy" rating restated by equities research analysts at D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $5.00 price target on the stock.

Separately, Jones Trading upgraded VolitionRx to a "strong-buy" rating and set a $3.00 target price for the company in a research note on Tuesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $3.50.

VolitionRx Stock Up 4.8%

Shares of NYSE VNRX traded up $0.03 during midday trading on Monday, hitting $0.63. 238,926 shares of the company's stock were exchanged, compared to its average volume of 196,454. VolitionRx has a 12 month low of $0.40 and a 12 month high of $0.94. The company's 50 day moving average price is $0.66 and its 200 day moving average price is $0.60. The firm has a market capitalization of $68.22 million, a PE ratio of -1.76 and a beta of 1.27.

Insiders Place Their Bets

In related news, Director Guy Archibald Innes bought 78,125 shares of the business's stock in a transaction dated Tuesday, August 5th. The stock was purchased at an average cost of $0.64 per share, for a total transaction of $50,000.00. Following the transaction, the director owned 966,814 shares in the company, valued at $618,760.96. The trade was a 8.79% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Cameron John Reynolds bought 78,125 shares of the business's stock in a transaction dated Tuesday, August 5th. The shares were bought at an average price of $0.64 per share, with a total value of $50,000.00. Following the completion of the transaction, the chief executive officer owned 2,609,847 shares in the company, valued at approximately $1,670,302.08. This trade represents a 3.09% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 171,250 shares of company stock valued at $109,900. Corporate insiders own 10.40% of the company's stock.

Institutional Trading of VolitionRx

A number of institutional investors have recently modified their holdings of VNRX. Northern Trust Corp lifted its position in shares of VolitionRx by 32.0% during the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company's stock valued at $71,000 after acquiring an additional 28,579 shares during the period. Millennium Management LLC acquired a new position in shares of VolitionRx during the 4th quarter worth $36,000. Silverberg Bernstein Capital Management LLC raised its holdings in shares of VolitionRx by 42.8% during the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 200,782 shares of the company's stock worth $153,000 after buying an additional 60,209 shares in the last quarter. Blair William & Co. IL acquired a new position in shares of VolitionRx during the 2nd quarter worth $30,000. Finally, Northwestern Mutual Wealth Management Co. acquired a new position in shares of VolitionRx during the 2nd quarter worth $52,000. 8.09% of the stock is currently owned by institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.